Repligen to Report Third Quarter 2018 Financial Results
October 22 2018 - 7:30AM
- Webcast and Conference Call to Be Held
Thursday, November 1, 2018 at 8:30 a.m. EDT -
Repligen Corporation (NASDAQ:RGEN) today announced that the Company
will report its third quarter of 2018 financial results on
Thursday, November 1, 2018. The Company will issue a press release
before the market opens and will host a conference call at 8:30
a.m. EDT to discuss business updates and financial results for the
three- and nine-month reporting periods ended September 30,
2018. The conference call will be accessible by dialing
toll-free (866) 777-2509 for domestic callers and (412) 317-5413
for international callers. No passcode is required for the live
call. In addition, a webcast will be accessible via the Investor
Relations section of the Company’s website. Both the conference
call and webcast will be archived for a period of time following
the live event. The replay dial-in numbers are (877) 344-7529 for
callers in the U.S., (855) 669-9658 for callers in Canada and (412)
317-0088 for international callers. Replay listeners must provide
the passcode 10125616.
About
Repligen CorporationRepligen Corporation (NASDAQ:RGEN) is
a global bioprocessing company that develops and commercializes
highly innovative products that deliver cost and process
efficiencies to biological drug manufacturers worldwide. Our
portfolio includes protein products (Protein A affinity ligands,
cell culture growth factors), chromatography products (OPUS®
pre-packed columns, chromatography resins, ELISA kits) and
filtration products (XCell™ ATF systems, TangenX™ SIUS™ flat sheet
TFF cassettes, and Spectrum KrosFlo™ hollow fiber TFF cartridges
and systems). The Protein A ligands and growth factor products that
we produce are key components of Protein A affinity resins and cell
culture media, respectively. Protein A affinity resins are the
industry standard for downstream separation and purification of
monoclonal antibody-based therapeutics. Growth factors are used in
upstream processes to accelerate cell growth and productivity. Our
innovative line of OPUS® chromatography columns, used in downstream
processes for bench-scale to commercial-scale purification needs,
are delivered pre-packed and customized to our customers choice of
resin and packed bed height. Our XCell™ ATF Systems, available in
stainless steel and single-use configurations, continuously
eliminate waste from a bioreactor to concentrate cells and
significantly increase productivity in upstream processes.
Single-use SIUS™ TFF cassettes and hardware are used for biologic
drug concentration in downstream filtration processes. Spectrum
KrosFlo™ TFF cartridges and systems are used in both upstream and
downstream filtration processes. Repligen’s corporate headquarters
are in Waltham, MA (USA), with additional administrative and
manufacturing operations at locations including Shrewsbury, MA,
Rancho Dominguez, CA, Lund, Sweden and Ravensburg, Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Source: Repligen Corporation Sondra Newman Senior Director
Investor Relations(781) 419-1881 snewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024